Clinical

The late-stage research of Bristol Myers’ heart disease medication falls short of its primary objectives

Bristol Myers Squibb disclosed that its drug stavartanate did not successfully improve functional capacity or symptom intensities in heart disease patients, thus failing to...

Pfizer Decides Against Pursuing Lead Obesity Asset Amid Liver Safety Concerns

Pfizer said that it had discovered a possible instance of medication-induced liver impairment and, as a result, would no longer be investing in the...

Rallybio Drops Maternal Disorder Drug Following Phase 2 Failure

US-based biotechnology company Rallybio is discontinuing its RLYB212 program for preventing the development of fetal and neonatal alloimmune thrombocytopenia (FNAIT) due to unsatisfactory outcomes...

Roche Reports Promising Early Data on Alzheimer’s Drug Trontinemab

Roche has disclosed preliminary findings regarding its investigational Alzheimer’s therapy, trontinemab. Early-stage data from the phase 1b/2a study indicate that amyloid levels in 81%...

Immunovant will not pursue approval for the autoimmune medication

The latest Phase 3 trial results for Immunovant’s batoclimab drug showed achievement of the main study objective. Since it selected a new second-generation molecule...

GSK Provides Insight Into Potential HIV Treatment Data

GSK’s ViiV Healthcare has disclosed clinical data about three prospective long-acting HIV therapies, offering insight into the development of its six-month therapy regimen. ViiV, primarily...

Pfizer and Arvinas disclose mixed breast cancer survival findings for PROTAC degrader

Pfizer and Arvinas reported that their estrogen receptor degrader failed to meet positive results in a major stage of its first phase 3 trial....

J&J Halts Phase 3 Depression Program Over Efficacy Concerns

Johnson & Johnson has contributed to the ongoing issues surrounding opioids. Months after Neumora's phase 3 failure, J&J has halted the development of its...

Latest news

Merck Signs $493M Agreement to Use Cyprumed’s Oral Peptide Platform

Merck & Co. is taking a significant step toward transforming its peptide therapies into convenient oral tablets through a...

The late-stage research of Bristol Myers’ heart disease medication falls short of its primary objectives

Bristol Myers Squibb disclosed that its drug stavartanate did not successfully improve functional capacity or symptom intensities in heart...

J&J MedTech presents the first Ottava surgical robot clinical cases

Johnson & Johnson MedTech successfully conducted the initial clinical use of Ottava surgical robot through a minimally invasive gastric...

Must read

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm

You might also likeRELATED
Recommended to you

Softbank now has $5B stake in Roche for its ability to develop drugs using data

The Japanese multinational group, SoftBank Group Corp.,...

FDA receives application for Parkinson’s treatment by AbbVie

AbbVie, an American Biopharmaceutical company, has submitted...